AN APPROACH TO THE MANAGEMENT OF TUBERCULOSIS IN HIV ENDEMIC AREAS

被引:6
作者
ELLIOTT, AM
机构
[1] School of Medicine, University of Zambia, London School of Hygiene and Tropical Medicine
关键词
D O I
10.1177/004947559202200402
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The epidemic of HIV-associated tuberculosis is having a severe impact on tuberculosis control in sub-Saharan Africa, as well as the United States of America, and is expected to spread. Where facilities are limited, the association between HIV and sputum-smear negative tuberculosis hampers diagnosis; trials of anti-tuberculous therapy are indicated in some cases. Standard treatment regimens are effective, but thiacetazone should be avoided because of its association with severe, cutaneous adverse reactions. Treatment may have to be prolonged in HIV positive cases. Measures to maximize compliance with therapy are paramount. These include the use of the shortest possible regimens, of recognized potency, and emphasis on ensuring that the regimen is understood by and readily accessible to the patient.
引用
收藏
页码:147 / 150
页数:4
相关论文
共 11 条
[1]  
Kochi A., The global tuberculosis situation and the new control strategy of the World Health Organisation, Tubercle, 72, pp. 1-6, (1991)
[2]  
Culliton B.J., Drug resistant TB may bring epidemic, Nature, 356, (1992)
[3]  
Elliott A.M., The changing face of tuberculosis in HIV endemic areas, Postgrad Doctor Africa, 14, pp. 16-19, (1992)
[4]  
Chaisson R.E., Slutkin G., Tuberculosis and the human immunodeficiency virus infection, J Infect Dis, 159, pp. 96-100, (1989)
[5]  
Voetberg A., Lucas S.B., Tuberculosis or persistent generalised lymphadenopathy in HIV disease?, Lancet, 337, pp. 56-57, (1991)
[6]  
Nunn P., Kibuga D., Gathua S., Et al., Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis, Lancet, 337, pp. 627-630, (1991)
[7]  
Mitchison D.A., Basic mechanisms of chemotherapy, Chest, 76, pp. 771-781, (1979)
[8]  
Diagnosis and management of mycobacterial disease in persons with human T-lymphotrophic virus type III/lymphadenopathy-associated virus infection, MMWR, 35, pp. 448-452, (1986)
[9]  
Murray C.J.L., Styblo K., Rouillon A., Tuberculosis in developing countries: burden, intervention and cost, Bull Int Union Tuberc Lung Dis, 65, pp. 6-24, (1990)
[10]  
Fox W., Drug combinations and the bioavailability of rifampicin, Tubercle, 71, pp. 241-245, (1990)